F M Buffa
Overview
Explore the profile of F M Buffa including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
711
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ralli G, Carter R, McGowan D, Cheng W, Liu D, Teoh E, et al.
Breast Cancer Res
. 2022 May;
24(1):34.
PMID: 35581637
Background: PET imaging of 18F-fluorodeoxygucose (FDG) is used widely for tumour staging and assessment of treatment response, but the biology associated with FDG uptake is still not fully elucidated. We...
2.
OCathail S, Buffa F
Clin Oncol (R Coll Radiol)
. 2019 Apr;
31(6):337-340.
PMID: 30975523
No abstract available.
3.
Harris B, Barberis A, West C, Buffa F
Clin Oncol (R Coll Radiol)
. 2015 Aug;
27(10):547-60.
PMID: 26282471
Hypoxia is a feature of most solid tumours and is associated with a poor prognosis. The hypoxic environment can reduce the efficacy of radiotherapy and some chemotherapeutics, and has been...
4.
Generali D, Buffa F, Deb S, Cummings M, Reid L, Taylor M, et al.
Br J Cancer
. 2014 May;
111(1):46-54.
PMID: 24874483
Background: Stratification of patients for treatment of ductal carcinoma in situ (DCIS) is suboptimal, with high systemic overtreatment rates. Methods: A training set of 95 tumours from women with pure...
5.
Airley R, McHugh P, Evans A, Harris B, Winchester L, Buffa F, et al.
Br J Cancer
. 2013 Dec;
110(3):715-23.
PMID: 24366300
Background: The lipogenic transcription factor carbohydrate response element-binding protein (ChREBP) may play a key role in malignant progression of breast cancer by allowing metabolic adaptations to take place in response...
6.
Blick C, Ramachandran A, Wigfield S, McCormick R, Jubb A, Buffa F, et al.
Br J Cancer
. 2013 Jun;
109(1):50-9.
PMID: 23778527
Background: Non-muscle invasive (NMI) bladder cancer is characterised by increased expression and activating mutations of FGFR3. We have previously investigated the role of microRNAs in bladder cancer and have shown...
7.
Church D, Phillips B, Stuckey D, Barnes D, Buffa F, Manek S, et al.
Oncogene
. 2011 Nov;
31(31):3635-46.
PMID: 22120709
The tumour suppressor PTEN is a key negative regulator of the PI3K-Akt pathway, and is frequently either reduced or lost in human tumours. Murine genetic studies have confirmed that reduction...
8.
Coutts A, Pires I, Weston L, Buffa F, Milani M, Li J, et al.
Oncogene
. 2011 Jun;
30(48):4835-42.
PMID: 21625218
Junction-mediating and regulatory protein (JMY) is a novel p53 cofactor that regulates p53 activity during stress. JMY interacts with p300/CBP, which are ubiquitous transcriptional co-activators that interact with a variety...
9.
Gee H, Buffa F, Camps C, Ramachandran A, Leek R, Taylor M, et al.
Br J Cancer
. 2011 Mar;
104(7):1168-77.
PMID: 21407217
Background: To investigate small-nucleolar RNAs (snoRNAs) as reference genes when measuring miRNA expression in tumour samples, given emerging evidence for their role in cancer. Methods: Four snoRNAs, commonly used for...
10.
Buffa F, Harris A, West C, Miller C
Br J Cancer
. 2010 Jan;
102(2):428-35.
PMID: 20087356
Background: There is a need to develop robust and clinically applicable gene expression signatures. Hypoxia is a key factor promoting solid tumour progression and resistance to therapy; a hypoxia signature...